Vivacta Biotechnology
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
$50MSeries A+
Role not disclosedAC
Apricot Capital
Activity from announced rounds
Activity in this selectionvictor-riparbelli-f4aa0359
- Rounds participated in
- 4
- Confirmed lead rounds
- — 4 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $192.7M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionVivatides Therapeutics
Develops extrahepatic RNA-targeting therapeutics
$54MSeries A
Role not disclosedExcalipoint Therapeutics
Develops next-generation T-cell engager therapies for cancer and autoimmune diseases
$27.7MSeed+
Role not disclosedVibrant Therapeutics
Develops intelligent, logic-gated therapeutics for solid tumors
$61MSeries A
Role not disclosed